Atacand Approved for Chronic Heart Failure Treatment

Published: 2004-12-03 06:57:00

Updated: 2004-12-03 06:57:00

AstraZeneca’s Atacand (candesarten cilexetil), an Angiotensin II Receptor Blocker (ARB) for the treatment of hypertension, has been additionally approved for the treatment of Chronic Heart Failures (CHF) by passing the European Mutual Recognition Procedure. This indicates that Atacand is now approved for marketing and sale in the European Union member countries.

The company stated that the ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.